<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39081650</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Nirmatrelvir-Ritonavir for Acute&#xa0;COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection.</ArticleTitle><Pagination><StartPage>100961</StartPage><MedlinePgn>100961</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100961</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2024.100961</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">There is limited evidence of association of nirmatrelvir-ritonavir (NMV-r) and incidence of postacute sequelae of SARS-CoV-2 infection (PASC) in patients with pre-existing cardiovascular disease (CVD).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The objective of this study was to assess the association of NMV-r in nonhospitalized, vaccinated patients with pre-existing CVD and occurrence of PASC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a retrospective cohort study utilizing the TriNetX research network, including vaccinated patients with pre-existing CVD who developed COVID-19 between December 2021 and December 2022. Two cohorts were created based on NMV-r administration within 5&#xa0;days of diagnosis: NMV-r and non-NMV-r cohort. The main outcome was presence of PASC, assessed between 30 to 90&#xa0;days and 90 to 180&#xa0;days after index COVID-19 infection. After propensity score matching, both cohorts were compared using t-test and chi-square test for continuous and categorical variables, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 26,953 patients remained in each cohort after propensity score matching. Broadly defined PASC occurred in 6,925 patients (26%) in the NMV-r cohort vs 8,150 patients (30.6%) in the non-NMV-r cohort (OR: 0.80; 95% CI: 0.76-0.82; <i>P</i>&#xa0;&lt;&#xa0;0.001) from 30 to 90&#xa0;days and in 6,692 patients (25.1%) as compared to 8,910 patients (33.5%) (OR: 0.25, 95% CI: 0.23-0.29; <i>P</i>&#xa0;&lt;&#xa0;0.001) from 90 to 180&#xa0;days. Similarly, narrowly defined PASC occurred in 5,335 patients (20%) in the NMV-r cohort vs 6,271 patients (23.6%) in the non-NMV-r cohort between 30 and 90&#xa0;days (OR:&#xa0;0.81, 95% CI: 0.78-0.84, <i>P</i>&#xa0;&lt;&#xa0;0.001) and in 5,121 patients (19.2%) as compared to 6,964 patients (26.1%) (OR:&#xa0;0.67, 95% CI: 0.64-0.70, <i>P</i>&#xa0;&lt;&#xa0;0.001) between 90 and 180&#xa0;days.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">NMV-r in nonhospitalized vaccinated patients with pre-existing CVD with COVID-19 was associated with&#xa0;a reduction in PASC and health care utilization.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Rushin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>Sourbha S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khadke</LastName><ForeName>Sumanth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Javaria</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saji</LastName><ForeName>Anu Mariam</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Jui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Neev</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wener</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuillen</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faust</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maley</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Lahey Hospital and Medical Centre, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullington</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wachter</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosenthal</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Academic Affairs, Lahey Hospital and Medical Center, Tufts University School of Medicine, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sax</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganatra</LastName><ForeName>Sarju</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">health care utilization</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">nirmatrelvir-ritonavir</Keyword><Keyword MajorTopicYN="N">postacute sequelae of SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>The authors have reported that they have no relationships relevant to the contents of this paper to disclose.PERSPECTIVESCOMPETENCY IN MEDICAL KNOWLEDGE: In a retrospective analysis, there is a significant risk reduction in PASC burden in high-risk patients with pre-existing CVD receiving NMV-r for the treatment of acute COVID-19 suggesting an association between treatment with NMV-r and a reduced incidence of the symptoms commonly reported with PASC. TRANSLATIONAL OUTLOOK: Prospective studies in the form of randomized controlled trials are urgently needed to understand the potential effect of antiviral therapy on the incidence of PASC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39081650</ArticleId><ArticleId IdType="pmc">PMC11286995</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2024.100961</ArticleId><ArticleId IdType="pii">S2772-963X(24)00146-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>del Rio C., Collins L.F., Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324:1723&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando H.M., Bennett T.D., Byrd J.B., et al. Challenges in defining long COVID: striking differences across literature, electronic health records, and patient-reported information. medRxiv. Posted March 26, 2021 doi: 10.1101/2021.03.20.21253896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.20.21253896</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfein J. Number of coronavirus (COVID-19) cases, recoveries, and deaths worldwide. 2022. www.statista.com</Citation></Reference><Reference><Citation>Ganatra S., Dani S.S., Redd R., et al. Outcomes of COVID-19 in patients with a history of cancer and comorbid cardiovascular disease. J&#xa0;Natl Compr Canc Netw. 2020:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33142266</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183(6):566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N&#xa0;Engl J Med. 2022;386:1397&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N&#xa0;Engl J Med. 2022;386:509&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N&#xa0;Engl J Med. 2022;386:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  . 2022. FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant.https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-for-treatment-of-covid-19-that-retains-activity-against-omicron-variant-301480912.html</Citation></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv. Posted November 5, 2022 doi: 10.1101/2022.11.03.22281783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.03.22281783</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust J.S., Kumar A., Shah J., et al. Oral nirmatrelvir and ritonavir for Covid-19 in vaccinated, non-hospitalized adults, ages 18-50 years. Clin Infect Dis. 2023;77(9):1257&#x2013;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">37387690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S., Dani S.S., Ahmad J., et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019 (COVID-19) Clin Infect Dis. 2023;76(4):563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452095</ArticleId><ArticleId IdType="pubmed">35986628</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., Senussi Y., Manickas-Hill Z., et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2023;76(3):e487&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>TriNetX  . 2022. The Global Health Research Network.https://trinetx.com/community/</Citation></Reference><Reference><Citation>CDC . WebPage: Centre for Disease Control; 2022. Long COVID or Post-COVID Conditions.</Citation></Reference><Reference><Citation>World Health Organization  . 2022. Post COVID-19 Condition (Long COVID)https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:&#x223c;:text=Definition,explained%20by%20an%20alternative%20diagnosis</Citation></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Wulf Hanson S., Abbafati C., et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele T.J., Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneuse S., VanderWeele T.J., Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321:602&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">30676631</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVER  . 2022. Explore Research.https://recovercovid.org/</Citation></Reference><Reference><Citation>Swank Z., Senussi Y., Manickas-Hill Z., et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham S., Nohria A., Neilan T.G., et al. Cardiovascular drug interactions with nirmatrelvir/ritonavir in patients with COVID-19: JACC review topic of the week. J&#xa0;Am Coll Cardiol. 2022;80:1912&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9580069</ArticleId><ArticleId IdType="pubmed">36243540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Buse J.B., Liebovitz D.M., et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10&#xa0;months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Naggie S., Boulware D.R., Lindsell C.J., et al. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;328:1595&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587497</ArticleId><ArticleId IdType="pubmed">36269852</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler C.C., Hobbs F.D.R., Gbinigie O.A., et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>